Identification of typical miRNAs and target genes in hepatocellular carcinoma by DNA microarray technique

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 1, 2014, Pages 108-116

  He, T L ^a   Zheng, K L ^a   Li, G ^a   Song, B ^a   Zhang, Y J ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Differentially expressed miRNA; Hepatocellular carcinoma; Interaction network; Target gene

Indexed keywords

ACETOACETATE COENZYME A LIGASE; ACETYL COENZYME A SYNTHETASE; BIOLOGICAL MARKER; DNA; ENDOGLIN; ENDOGLIN 3; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE ISOENZYME; MICRORNA; NERVE CELL ADHESION MOLECULE; NERVE CELL ADHESION MOLECULE 1; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DNA MICROARRAY; EARLY DIAGNOSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MAPPING; GENE ONTOLOGY; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MACROMOLECULE; METABOLOMICS; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; RECEPTOR DOWN REGULATION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER TUMOR; METABOLISM; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER NEOPLASMS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84896982623     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. WALY RAPHAEL S., YANGDE Z, YUXIANG C. Hepatocellu-lar carcinoma: focus on different aspects of management. ISRN Oncol 2012; 2012: 421673.
2. YANG JD, ROBERTS LR Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010; 24: 899-919, viii.
3. HUANG XB, LI J, ZHENG L., ZUO GH, HAN KQ, LI HY, LIANG P. Bioinformatics analysis reveals potential candidate drugs for HCC. Pathol Oncol Res 2013; 19: 251-258.
4. ROUX J, GONZALEZ-PORTA M, ROBINSON-RECHAVI M. Comparative analysis of human and mouse expression data illuminates tissue-specific evolutionary patterns of miRNAs. Nucleic Acids Res 2012; 40: 5890-5900.
5. KOZOMARA A, GRIFFITHS-JONES S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39: 152-157.
6. Carthew RW, Sontheimer EJ Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-655.
7. SOMEL M, GUO S, FU N., YAN Z, HU H Y, XU Y, YUAN Y., NING Z, HU Y, MENZEL C. MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res 2010; 20: 1207-1218.
8. SOMEL M, LIU X, TANG L., YAN Z, HU H, GUO S., JIANG X, ZHANG X, XU G, XIE G, LI N, HU Y, CHEN W, PAABO S, KHAITOVICH P. MicroRNA-driven developmental remodeling in the brain distinguishes humans from other primates. PLoS Biol 2011; 9: e1001214.
9. BOREL F, KONSTANTINOVA P, JANSEN PL Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56: 1371-1383.
10. BRACONI C, HENRY JC, KOGURE T, SCHMITTGEN T., PATEL T. The role of microRNAs in human liver cancers. Semin Oncol 2011; 38: 752-763.
11. HUANG S, HE X. The role of microRNAs in liver cancer progression. Br J Cancer 2011; 104: 235-240.
12. LAW PT, WONG N. Emerging roles of microRNA in the intracellular signaling networks of hepatocel-lular carcinoma. J Gastroenterol Hepatol 2011; 26: 437-449.
13. FURUTA M, KOZAKI K, TANIMOTO K., TANAKA S, ARII S, SHIMAMURA T., NIIDA A, MIYANO S, INAZAWA J. The tu-mor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One 2013; 8: e60155.
14. BEST CJ, GILLESPIE JW, YI Y, CHANDRAMOULI G V, PERLMUTTER MA, GATHRIGHT Y, ERICKSON H.S., GEORGEVICH L., TANGREA MA, DURAY PH, GONZALEZ S, VELASCO A, LINEHAN WM, MATUSIK RJ, PRICE DK, FIGG WD, EM-MERT-BUCK MR, CHUAQUI RF. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005; 11: 6823-6834.
15. SMYTH GK, YANG YH, SPEED T. Statistical issues in cDNA microarray data analysis. Methods Mol Biol 2003; 224: 111-136.
16. EISEN MB, SPELLMAN PT, BROWN P.O., BOTSTEIN D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95: 14863-14868.
17. XIAO F, ZUO Z, CAI G., KANG S, GAO X, LI T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009; 37: 105-110.
18. HSU SD, LIN FM, WU W.Y., LIANG C., HUANG WC, CHAN WL, TSAI WT, CHEN G.Z., LEE CJ, CHIU CM, CHIEN CH, WU MC, HUANG CY, TSOU A P, HUANG HD. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 2011; 39: 163-169.
19. SZKLARCZYK D, FRANCESCHINI A, KUHN M., SIMONOVIC M, ROTH A, MINGUEZ P., DOERKS T, STARK M, MULLER J, BORK P, JENSEN LJ, VON MERING C. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011; 39: 561-568.
20. SMOOT ME, ONO K, RUSCHEINSKI J., WANG PL, IDEKER T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011; 27: 431-432.
21. BANDETTINI W.P., KELLMAN P, MANCINI C., BOOKER OJ, VASU S, LEUNG SW, WILSON J.R., SHANBHAG SM, CHEN MY, ARAI AE. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson 2012; 14: 83.
22. MAERE S, HEYMANS K, KUIPER M. BiNGO: a Cy-toscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005; 21: 3448-3449.
23. RIVERA CG, VAKIL R, BADER JS NeMo: Network Module identification in Cytoscape. BMC Bioinformat-ics 2010; 11(Suppl 1): S61.
24. NORDENSTEDT H, WHITE DL, EL-SERAG HB. The changing pattern of epidemiology in hepatocellu-lar carcinoma. Dig Liver Dis 2010; 42(SUPPL. 3): S206-214.
25. NEGRINI M, GRAMANTIERI L, SABBIONI S., CROCE CM microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 2011; 11: 500-521.
26. LAGOS-QUINTANA M., RAUHUT R, YALCIN A., MEYER J, LENDECKEL W, TUSCHL T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739.
27. LINDOW M, KAUPPINEN S. Discovering the first mi-croRNA-targeted drug. J Cell Biol 2012; 199: 407-412.
28. JOPLING C. Liver-specific microRNA-122: Biogenesis and function. RNA Biol 2012; 9: 137-142.
29. KUTAY H, BAI S, DATTA J., MOTIWALA T, POGRIBNY I, FRANKEL W., JACOB ST, GHOSHAL K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-678.
30. BURCHARD J, ZHANG C, LIU A.M., POON RT, LEE N P, WONG K-F, SHAM PC, LAM B.Y., FERGUSON MD, TOKIWA G. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol 2010; 6: 402.
31. FAN CG, WANG CM, TIAN C, WANG Y., LI L, SUN WS, LI R F, LIU YG. miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepa-tocellular carcinoma and targets NDRG3. Oncol Rep 2011; 26: 1281-1286.
32. GOOZ M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010; 45: 146-169.
33. TSAI WC, HSU PWC, LAI TC, CHAU G.Y., LIN CW, CHEN CM, LIN CD, LIAO YL, WANG JL, CHAU YP. MicroRNA©\122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepato-cellular carcinoma. Hepatology 2009; 49: 1571-1582.
34. WANG X-J, FENG C-W, LI M. ADAM17 mediates hy-poxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem 2013; 380: 57-66.
35. OISHI N, KUMAR MR, ROESSLER S, JI J., FORGUES M, BUDHU A, ZHAO X., ANDERSEN JB, YE QH, JIA HL, QIN LX, YAMASHITA T, WOO HG, KIM YJ, KANEKO S, TANG ZY, THORGEIRSSON SS, WANG XW. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangio-carcinoma. Hepatology 2012; 56: 1792-1803.
36. TSUCHIYA A, KAMIMURA H, TAMURA Y., TAKAMURA M, YA-MAGIWA S, SUDA T, NOMOTO M., AOYAGI Y. Hepatocel-lular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker NCAM. Cancer Lett 2011; 309: 95-103.
37. GINOUVES A, ILC K, MACIAS N., POUYSSEGUR J, BERRA E. PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis. Proc Natl Acad Sci U S A 2008; 105: 4745-4750.
38. WANG ZC, GAO Q, SHI J.Y., YANG LX, ZHOU J, WANG XY, SHI Y.H., KE AW, SHI GM, DING ZB, DAI Z, QIU SJ, FAN J. Genetic polymorphism of the kinesin-like protein KIF1B gene and the risk of hepatocellular carcinoma. PLoS One 2013; 8: e62571.
39. ZHANG H, ZHAI Y, HU Z., WU C, QIAN J, JIA W., MA F, HUANG W, YU L, YUE W. Genome-wide association study identifies 1p36. 22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010; 42: 755-758.
40. LESSA RC, CAMPOS AH, DE FREITAS CE, DA SILVA FR, KOWALSKI L P, CARVALHO AL, VETTORE AL. Identification of upregulated genes in oral squamous cell carcinomas. Head Neck 2013; 35: 1475-1481.
41. OTTO E, KUNIMOTO M, MCLAUGHLIN T., BENNETT V. Isolation and characterization of cDNAs encoding human brain ankyrins reveal a family of alternatively spliced genes. J Cell Biol 1991; 114: 241-253.
42. LEUSSIS M.P., MADISON JM, PETRYSHEN TL Ankyrin 3: genetic association with bipolar disorder and relevance to disease pathophysiology. Biol Mood Anxiety Disord 2012; 2: 18.
43. MOHLER PJ, SCHOTT JJ, GRAMOLINI A.O., DILLY KW, GUATIMOSIM S, DUBELL WH, SONG L.S., HAUROGNE K., KYNDT F, ALI ME, ROGERS TB, LEDERER WJ, ESCANDE D, LE MAREC H, BENNETT V. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421: 634-639.
44. KIRPICH IA, GOBEJISHVILI LN, BON HOMME M, WAIGEL S, CAVE M., ARTEEL G, BARVE SS, MCCLAIN CJ, DEACIUC IV. Integrated hepatic transcriptome and pro-teome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J Nutr Biochem 2011; 22: 38-45.
45. LUTASA MU, SALIS F, UR TASUN R, GARCIA-IRIGOYEN O, ELIZALDE M.A., URIARTE I., SANTAMARIA M, FEO F, PASCALE RM, PRIETO JS. Regulation of Amphiregulin gene expression by -catenin signaling in human Hepa-tocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PLoS One 2012; 7: e52711.
46. URTASUN R, LATASA MU, DEMARTIS M.I., BALZANI S., GONI S, GARCIA-IRIGOYEN O, ELIZALDE M, AZCONA M., PASCALE RM, FEO F, BIOULAC-SAGE P, BALABAUD C, MUNTANE J, PRIETO J, BERASAIN C, AVILA MA. Connective tissue growth factor autocriny in human hepatocellular carcinoma: onco-genic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 2011; 54: 2149-2158.
47. KENG VW, SIA D, SARVER A.L., TSCHIDA BR, FAN D, ALSINET C, SOL M., LEE WL, KUKA T P, MORIARITY BS. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology 2013; 57: 120-130.
48. ZHU XW, GONG JP Expression and role of icam-1 in the occurrence and development of hepatocel-lular carcinoma. Asian Pac J Cancer Prev 2013; 14: 1579-1583.
49. ROTTIERS V, NAAR AM MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13: 239-250.
50. CHEN B, LI H, ZENG X., YANG P, LIU X, ZHAO X., LIANG S. Roles of microRNA on cancer cell metabolism. J Transl Med 2012; 10: 228.
51. HATZIAPOSTOLOU M, POLYTARCHOU C, ILIOPOULOS D. miRNAs link metabolic reprogramming to oncoge-nesis. Trends Endocrinol Metab 2013; 24: 361-373.
52. WU JM, SKILL NJ, MALUCCIO MA Evidence of aberrant lipid metabolism in hepatitis C and hepato-cellular carcinoma. HPB (Oxford) 2010; 12: 625-636.
53. BECKER D, SFAKIANAKIS I, KRUPP M., STAIB F, GERHOLD-AY A, VICTOR A, BINDER H., BLETTNER M, MAASS T, THORGEIRSSON S, GALLE PR, TEUFEL A. Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. Mol Cancer 2012; 11: 55.